Telix Pharmaceuticals Limited (TLX) revenue breakdown
By segment, Precision Medicine is the largest at 77% of fiscal 2025 revenue; Manufacturing Solutions grew fastest, 2396% a year over 2 years.
By region, United States is the largest at 98% of fiscal 2025 revenue, growing 74% a year over 3 years.
Revenue by segment
Fiscal years, as Telix Pharmaceuticals Limited reports them in its 10-K filings; fiscal 2025 total $804M.
| Segments | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| Precision Medicine | $156M | $329M | $509M | $622M | 77% |
| Manufacturing Solutions | — | $277,000 | $2M | $173M | 21% |
| Therapeutics | $4M | $3M | $6M | $9M | 1% |
Revenue by region
Fiscal years, as Telix Pharmaceuticals Limited reports them in its 10-K filings; fiscal 2025 total $804M.
| Regions | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| United States | $150M | $324M | $503M | $785M | 98% |
| China | — | $863,000 | $382,000 | $10M | 1% |
| Other countries | $7M | $8M | $13M | $9M | 1% |
| United Kingdom | $2M | — | — | — | — |
| Belgium | $564,000 | — | — | — | — |
| Canada | $456,000 | — | — | — | — |
| Australia | $149,000 | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TLX.
Open TLX in InvestinglyQuestions
Where does Telix Pharmaceuticals Limited make its money?
In fiscal 2025, by segment: Precision Medicine $622M, Manufacturing Solutions $173M, Therapeutics $9M.
From Telix Pharmaceuticals Limited's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.